 |
23 Diseases |  |
21 Trials |
|
21 Trials |  |
1283 News |  |
| «12...567891011121314151617» |
- Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date, Metastases: Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors (clinicaltrials.gov) - May 31, 2017
P1, N=18, Not yet recruiting, Sponsor: Amgen
Trial primary completion date: Mar 2019 --> Feb 2020
- | Imlygic (talimogene laherparepvec) / Amgen
Review, Journal: Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. (Pubmed Central) - May 28, 2017
Many unanswered questions remain, including how to augment these clinical responses and which other tumor types may respond to oncolytic therapy. Here, we review the development of T-Vec, our current understanding of its impact on the tumor immune micro-environment, and its safety and efficacy in clinical trials for melanoma and other cancers.
- ||| Imlygic (talimogene laherparepvec) / Amgen
Enrollment closed, Surgery: Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma (clinicaltrials.gov) - May 22, 2017
P2, N=150, Active, not recruiting, Sponsor: Amgen
Here, we review the development of T-Vec, our current understanding of its impact on the tumor immune micro-environment, and its safety and efficacy in clinical trials for melanoma and other cancers. Recruiting --> Active, not recruiting
- Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date, Metastases: TVEC and Preop Radiation for Sarcoma (4 ml Dose) (clinicaltrials.gov) - Apr 24, 2017
P1/2, N=32, Recruiting, Sponsor: Mohammed M Milhem
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2017 --> Apr 2018
- || Imlygic (talimogene laherparepvec) / Amgen
Trial initiation date: Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=920, Not yet recruiting, Sponsor: Amgen
Trial primary completion date: Apr 2017 --> Apr 2018 Initiation date: Apr 2017 --> Aug 2017
- | Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma (clinicaltrials.gov) - Mar 31, 2017
P2, N=26, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Apr 2017 --> Aug 2017 Not yet recruiting --> Recruiting
- Imlygic (talimogene laherparepvec) / Amgen
Enrollment open: Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma (clinicaltrials.gov) - Mar 28, 2017
P1, N=18, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Imlygic (talimogene laherparepvec) / Amgen
Enrollment open, Combination therapy: Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov) - Mar 28, 2017
P1/2, N=46, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Imlygic (talimogene laherparepvec) / Amgen
New P1 trial, Metastases: Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer (clinicaltrials.gov) - Mar 22, 2017
P1, N=16, Not yet recruiting, Sponsor: Yvonne Saenger
- | New P1 trial, Combination therapy, Metastases: Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma (clinicaltrials.gov) - Mar 21, 2017
P1b, N=20, Not yet recruiting, Sponsor: West Cancer Center
- | Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Metastases: A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma (clinicaltrials.gov) - Mar 3, 2017
P2, N=26, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Imlygic (talimogene laherparepvec) / Amgen
New P1 trial: Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma (clinicaltrials.gov) - Feb 27, 2017
P1, N=18, Not yet recruiting, Sponsor: Amgen
- Imlygic (talimogene laherparepvec) / Amgen
Phase classification: Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma (clinicaltrials.gov) - Feb 24, 2017
P3b, N=0, Available, Sponsor: Amgen
Not yet recruiting --> Recruiting Phase classification: P3 --> P3b
- || Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date: KEYNOTE-034: Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (clinicaltrials.gov) - Feb 9, 2017
P1b, N=660, Recruiting, Sponsor: Amgen
Phase classification: P3 --> P3b Trial primary completion date: May 2018 --> Dec 2018
- | Imlygic (talimogene laherparepvec) / Amgen
Phase classification: Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=920, Not yet recruiting, Sponsor: Amgen
Trial primary completion date: May 2018 --> Dec 2018 Phase classification: P4 --> P=N/A
- Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date, Metastases: MASTERKEY 232: Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) (clinicaltrials.gov) - Jan 24, 2017
P1b, N=40, Recruiting, Sponsor: Amgen
Phase classification: P4 --> P=N/A Trial primary completion date: Apr 2019 --> Jun 2021
- |||| Provecta (rose bengal sodium) / Provectus
Trial primary completion date, Oncolytic virus, Metastases: PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma (clinicaltrials.gov) - Jan 9, 2017
P3, N=225, Recruiting, Sponsor: Provectus Biopharmaceuticals, Inc.
Trial primary completion date: Apr 2019 --> Jun 2021 Trial primary completion date: Mar 2018 --> Sep 2018
- || Imlygic (talimogene laherparepvec) / Amgen
Trial initiation date: Registry Study for Talimogene Laherparepvec (clinicaltrials.gov) - Dec 13, 2016
P=N/A, N=450, Enrolling by invitation, Sponsor: Amgen
Trial primary completion date: Mar 2018 --> Sep 2018 Initiation date: Dec 2014 --> Apr 2010
- Imlygic (talimogene laherparepvec) / Amgen
Trial initiation date, Trial primary completion date, Metastases: Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors (clinicaltrials.gov) - Dec 8, 2016
P1, N=18, Not yet recruiting, Sponsor: Amgen
Initiation date: Dec 2014 --> Apr 2010 Initiation date: Nov 2016 --> Feb 2017 | Trial primary completion date: Jul 2018 --> Mar 2019
- | Imlygic (talimogene laherparepvec) / Amgen, Opdivo (nivolumab) / BMS
New P2 trial, PD(L)-1 Biomarker, IO biomarker: NCI#10057: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (clinicaltrials.gov) - Dec 1, 2016
P2, N=68, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Imlygic (talimogene laherparepvec) / Amgen
Trial initiation date, Combination therapy: Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 17, 2016
P1/2, N=46, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Initiation date: Nov 2016 --> Feb 2017 | Trial primary completion date: Jul 2018 --> Mar 2019 Initiation date: Nov 2016 --> Feb 2017
- | Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: S1607: Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov) - Nov 17, 2016
P2, N=64, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Imlygic (talimogene laherparepvec) / Amgen
Trial initiation date: Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC (clinicaltrials.gov) - Nov 15, 2016
P4, N=920, Not yet recruiting, Sponsor: Amgen
Initiation date: Nov 2016 --> Feb 2017 Initiation date: Nov 2016 --> Feb 2017
- || Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date: Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC (clinicaltrials.gov) - Oct 21, 2016
P4, N=920, Not yet recruiting, Sponsor: Amgen
Initiation date: Nov 2016 --> Feb 2017 Trial primary completion date: Aug 2019 --> Aug 2024
- Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date, Metastases: MASTERKEY 232: Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) (clinicaltrials.gov) - Oct 12, 2016
P1b, N=40, Recruiting, Sponsor: Amgen
Trial primary completion date: Aug 2019 --> Aug 2024 Trial primary completion date: Aug 2019 --> Apr 2019
- | Imlygic (talimogene laherparepvec) / Amgen
Phase classification: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Oct 7, 2016
P1b/2, N=217, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Aug 2019 --> Apr 2019 Phase classification: P1/2 --> P1b/2
- ||| ontorpacept intratumoral (TTI 621 intratumoral) / Pfizer
Enrollment open: Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides (clinicaltrials.gov) - Oct 6, 2016
P1, N=54, Recruiting, Sponsor: Trillium Therapeutics Inc.
Phase classification: P1/2 --> P1b/2 Not yet recruiting --> Recruiting
- Imlygic (talimogene laherparepvec) / Amgen
New P2 trial, IO biomarker, Surgery: Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - Oct 5, 2016
P2, N=40, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Imlygic (talimogene laherparepvec) / Amgen
New P4 trial: Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC (clinicaltrials.gov) - Sep 22, 2016
P4, N=920, Not yet recruiting, Sponsor: Amgen
- ||| ontorpacept intratumoral (TTI 621 intratumoral) / Pfizer
New P1 trial: Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides (clinicaltrials.gov) - Sep 7, 2016
P1, N=54, Not yet recruiting, Sponsor: Trillium Therapeutics Inc.
- ||| Imlygic (talimogene laherparepvec) / Amgen
Enrollment closed, Trial primary completion date: Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Aug 4, 2016
P2, N=112, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Jun 2017
- Imlygic (talimogene laherparepvec) / Amgen
Phase classification, Metastases: MASTERKEY 232: Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) (clinicaltrials.gov) - Aug 3, 2016
P1b, N=40, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Jun 2017 Phase classification: P1 --> P1b
- | Imlygic (talimogene laherparepvec) / Amgen
Enrollment open, Surgery: Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 3, 2016
P2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P1 --> P1b Not yet recruiting --> Recruiting
- | Imlygic (talimogene laherparepvec) / Amgen
New P2 trial: A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors (clinicaltrials.gov) - Jun 30, 2016
P2, N=34, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Imlygic (talimogene laherparepvec) / Amgen
Phase classification: KEYNOTE-034: Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (clinicaltrials.gov) - Jun 28, 2016
P1b, N=660, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Phase classification: P3 --> P1b
- | Imlygic (talimogene laherparepvec) / Amgen
New P1/2 trial, Combination therapy: Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov) - May 20, 2016
P1/2, N=46, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Provecta (rose bengal sodium) / Provectus
Trial primary completion date, Oncolytic virus, Metastases: PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma (clinicaltrials.gov) - May 13, 2016
P3, N=225, Recruiting, Sponsor: Provectus Biopharmaceuticals, Inc.
Phase classification: P3 --> P1b Trial primary completion date: Sep 2017 --> Mar 2018
- | Imlygic (talimogene laherparepvec) / Amgen
Trial initiation date, Trial primary completion date, Surgery: Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - May 2, 2016
P2, N=35, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2017 --> Mar 2018 Initiation date: Mar 2016 --> Jul 2016 | Trial primary completion date: Mar 2021 --> Jul 2021
- | Imlygic (talimogene laherparepvec) / Amgen
New P1 trial, Metastases: Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors (clinicaltrials.gov) - May 2, 2016
P1, N=18, Not yet recruiting, Sponsor: Amgen
- Imlygic (talimogene laherparepvec) / Amgen
Enrollment open, Metastases: MASTERKEY 232: Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) (clinicaltrials.gov) - Apr 21, 2016
P1, N=40, Recruiting, Sponsor: Amgen
Initiation date: Mar 2016 --> Jul 2016 | Trial primary completion date: Mar 2021 --> Jul 2021 Not yet recruiting --> Recruiting
- Imlygic (talimogene laherparepvec) / Amgen
Enrollment change, Trial primary completion date: Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer (clinicaltrials.gov) - Apr 15, 2016
P1, N=17, Completed, Sponsor: BioVex Limited
Not yet recruiting --> Recruiting N=30 --> 17 | Trial primary completion date: Mar 2010 --> Jan 2008
- || Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date: Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Apr 12, 2016
P2, N=110, Recruiting, Sponsor: Amgen
N=30 --> 17 | Trial primary completion date: Mar 2010 --> Jan 2008 Trial primary completion date: Aug 2017 --> Nov 2017
- ||| Imlygic (talimogene laherparepvec) / Amgen
Enrollment closed: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Mar 30, 2016
P1/2, N=217, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Aug 2017 --> Nov 2017 Recruiting --> Active, not recruiting
- ||| Imlygic (talimogene laherparepvec) / Amgen
Enrollment open, Pan tumor, Metastases: MASTERKEY318: Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 (clinicaltrials.gov) - Mar 14, 2016
P1, N=100, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Feb 29, 2016
P1/2, N=219, Recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Trial primary completion date: May 2016 --> Aug 2016
- || Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date, Pan tumor, Metastases: MASTERKEY318: Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 (clinicaltrials.gov) - Feb 18, 2016
P1, N=100, Not yet recruiting, Sponsor: Amgen
Trial primary completion date: May 2016 --> Aug 2016 Trial primary completion date: Sep 2017 --> Feb 2018
- || Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date: Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Feb 11, 2016
P2, N=110, Recruiting, Sponsor: Amgen
Trial primary completion date: Sep 2017 --> Feb 2018 Trial primary completion date: Dec 2017 --> Aug 2017
- |||||| Imlygic (talimogene laherparepvec) / Amgen
Enrollment open, Trial primary completion date: KEYNOTE-034: Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (clinicaltrials.gov) - Feb 11, 2016
P3, N=660, Recruiting, Sponsor: Amgen
Trial primary completion date: Dec 2017 --> Aug 2017 Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2018 --> May 2018
- Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date, Metastases: Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Feb 8, 2016
P3, N=5, Terminated, Sponsor: BioVex Limited
Active, not recruiting --> Recruiting | Trial primary completion date: Sep 2018 --> May 2018 Trial primary completion date: Jul 2011 --> Oct 2011
- || Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date, Surgery: Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma (clinicaltrials.gov) - Feb 3, 2016
P2, N=150, Recruiting, Sponsor: Amgen
Trial primary completion date: Jul 2011 --> Oct 2011 Trial primary completion date: Aug 2018 --> Nov 2018